Hypolipidemic effects of selective liver X receptor alpha agonists

Related Experiment Video

Updated: Oct 3, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

C Song1, S Liao

  • 1The Ben May Institute for Cancer Research, Department of Biochemistry and Molecular Biology, the Tang Center for Herbal Medicine Research, 5841 South Maryland Avenue, , Chicago, Illinois 60637, USA.

Steroids
|September 8, 2001
PubMed

Insights

Novel bile acid analogs activate liver X receptor alpha (LXRalpha), demonstrating a hypolipidemic effect in animal models. This suggests LXRalpha agonists may offer a new approach to cholesterol management.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Metabolic Diseases

Background:

  • Nuclear receptors, including liver X receptor alpha (LXRalpha) and ubiquitous receptor (UR), are crucial for cholesterol homeostasis.
  • LXRalpha plays a key role in cholesterol reverse transport and disposal, as evidenced by metabolic inflexibility in LXRalpha null mice on high-cholesterol diets.

Purpose of the Study:

  • To investigate the therapeutic potential of 6alpha-hydroxylated bile acid analogs as selective LXRalpha activators.
  • To evaluate the hypolipidemic effects and pharmacokinetic profile of these novel compounds in animal models of hypercholesterolemia.

Main Methods:

  • Administration of 6alpha-hydroxylated bile acid analogs to hypercholesterolemic rats, mice, and hamsters.
  • Assessment of hypolipidemic effects, including changes in cholesterol and triglyceride levels.
  • Evaluation of pharmacokinetic profiles of the bile acid analogs.

Main Results:

  • Orally administered LXRalpha agonists exhibited a significant hypolipidemic effect across all tested animal models.
  • Endogenous LXRalpha agonist appears to be a limiting factor in cholesterol disposal in these models.
  • The bile acid analogs demonstrated a unique pharmacokinetic profile and did not elevate serum triglyceride levels.

Conclusions:

  • 6alpha-hydroxylated bile acid analogs are effective LXRalpha agonists with hypolipidemic properties.
  • These compounds may represent a novel therapeutic class for managing cholesterol levels.
  • The findings suggest that LXRalpha activation is a viable strategy for enhancing cholesterol disposal.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...